Advanced Cell Technology (ACTC.OB) receives approval from an independent Data & Safety...

|By:, SA News Editor

Advanced Cell Technology (ACTC.OB) receives approval from an independent Data & Safety Monitoring Board to proceed with the next stage of three stem cell studies in the U.S. and Europe in people with the vision disorders Stargardts Macular Dystrophy and dry age-related macular degeneration. The two trials in the U.S. can include patients with better vision than previously allowed. (PR)